



Press Release

Paris, 16 April 2014

KURMA Partners invests in OxThera, first investment of its fund Kurma Biofund II

Kurma Partners, a key European player in the financing of Innovation in Healthcare and Biotechnology, announces its first investment of its fund Kurma Biofund II, the first Venture Capital fund dedicated to financing innovation in the rare diseases space, in OxThera, alongside Mayo Clinic, Idinvest Partners, and historical investors like Healthcap and Stiftelsen Industrifonden, for more than €7,5m.

OxThera, a Stockholm-based privately-held biopharmaceutical company, is currently conducting a placebo-controlled clinical trial with Oxabact® in patients with Primary Hyperoxaluria at seven clinical sites in three countries.

Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. The high medical need of PH is unmet to date.

Rémi Droller, Managing Partner of Kurma Partners, who joins the Board of Directors of OxThera commented: « *this first investment of Kurma Biofund II, is fully consistent with our investment strategy to support business innovation for Life Sciences in Europe, in a context where the development of new treatments and diagnostic tools for rare diseases is increasingly sought-after by industrialists seeking therapeutic innovation.* »

A propos de KURMA Partners - www.kurmapartners.com

KURMA Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I and II, and strategic partnerships with prestigious European research and medical institutions.

A propos de OxThera - www.oxthera.com

OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of primary hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for the treatment of oxalate malabsorption and kidney failure in enteric hyperoxaluria.

Press contacts

NewCap. - Nicolas Merigeau : +33(0)1 44 71 94 98 - nmerigeau@newcap.fr